Form 4: DENTSPLY SIRONA SVP to Receive 778K Future Stock Options

DENTSPLY SIRONA Inc.'s SVP, Chief Supply Chain Officer Robert Anthony Johnson, is scheduled to receive 778,900 stock options on November 7, 2025, under a Rule 10b5-1 plan.

Summary

• Robert Anthony Johnson, SVP, Chief Supply Chain Officer of DENTSPLY SIRONA Inc. (XRAY), is the reporting person.
• The filing indicates a transaction made pursuant to a Rule 10b5-1(c) plan.
• On November 7, 2025, Johnson is scheduled to acquire 417,200 stock options with an exercise price of $11.18 per share.
• Also on November 7, 2025, Johnson is scheduled to acquire an additional 361,700 stock options with an exercise price of $12.30 per share.
• The total number of stock options to be acquired is 778,900.
• Both tranches of options will cliff-vest and become exercisable on November 7, 2028, which is the third anniversary of the grant date.
• The options are set to expire on November 7, 2035.

Sentiment

Score: 7

Explanation: The filing reports a pre-scheduled grant of a substantial number of stock options to a key executive, which is a positive for executive retention and alignment of interests with shareholders over the long term. It reflects a planned compensation event rather than an immediate operational or financial performance update.

Positives

• The grant of a significant number of stock options (778,900) to a key executive (SVP, Chief Supply Chain Officer) aligns executive incentives with long-term shareholder value creation.
• The options have a 10-year expiration period, providing a substantial long-term incentive horizon for the executive.
• The transaction is made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged and transparent compensation structure.

Negatives

• No direct negatives are apparent from this routine executive compensation event.

Risks

• The value of the granted options is contingent on DENTSPLY SIRONA Inc.'s stock price appreciating above the exercise prices ($11.18 and $12.30) by the vesting date and remaining above those prices until exercise.
• If the company's stock price does not perform favorably, the options may not become 'in the money' or may lose value, potentially reducing the intended incentive effect.

Future Outlook

This Form 4 reports a future grant of stock options scheduled for November 7, 2025, with vesting to occur on November 7, 2028, and expiration on November 7, 2035. This indicates a long-term incentive structure for the executive, aligning their interests with the company's future performance over an extended period.

Industry Context

This transaction represents a standard executive compensation practice within the healthcare and dental equipment manufacturing industry, aiming to align executive incentives with long-term shareholder value creation. The use of a Rule 10b5-1 plan for future grants is also a common practice for managing insider transactions transparently.

Comparison to Industry Standards

• Granting stock options with vesting periods is a common practice across industries, including medical devices and dental supplies, to retain key talent and incentivize performance.
• The cliff-vesting schedule on the third anniversary is a typical structure for long-term incentive plans, comparable to practices at companies like Zimmer Biomet Holdings (ZBH) or Align Technology (ALGN) for executive retention.
• The exercise price for the second tranche being 110% of the closing price on the grant date is a premium option structure, sometimes used to provide a stronger incentive for significant stock price appreciation, similar to performance-based grants seen in other large-cap companies.

Stakeholder Impact

• Shareholders: Potential positive impact through increased executive incentive to drive long-term stock price appreciation. Future dilution from option exercise is a consideration but is typically managed within compensation plans.
• Management: The reporting person benefits directly from the compensation, aligning their financial interests with the company's long-term stock performance and retention.

Next Steps

• The reported stock options are scheduled to be granted on November 7, 2025.
• The options will cliff-vest and become exercisable on November 7, 2028.
• The options will expire on November 7, 2035.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event (a pre-scheduled stock option grant under a 10b5-1 plan) and does not provide sufficient new information to alter a fundamental investment thesis. It reinforces executive alignment but doesn't signal immediate operational changes or financial performance shifts that would warrant a 'buy' or 'sell' recommendation based solely on this filing.

Keywords

DENTSPLY SIRONA, XRAY, Stock Options, Executive Compensation, Form 4, Insider Transaction, Rule 10b5-1, Robert Anthony Johnson, Supply Chain Officer